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Functional magnetic resonance imag-ing has become a powerful tool
to investigate the neuroendocrinology of
appetite. In a recent study, we demon-
strated that the brain activation pattern
seen following the infusion of the
anorectic gut hormones PYY3–36 and
GLP-17–36 amide to fasted individuals
resembles the brain activation pattern
seen in the physiological satiated state.
This commentary discusses the signific-
ance of these findings and compares them
with other landmark studies in the field,
with specific reference to the brain areas
involved in appetite regulation. We high-
light the importance of this type of
research in order to pave the way for
the development of efficacious and safe
anti-obesity therapies.
Introduction
Effective pharmacotherapy to tackle
obesity remains an elusive goal, despite
an ever-growing need. In Europe, it is
currently estimated that 17% of the
population is obese; extrapolation of recent
trends predicts that by 2015, this figure
could rise to 30%.1 For the first time in
living memory, life expectancy in the West
is predicted to decrease as a result of
obesity-related health issues, particularly
diabetes and cardiovascular disease.2 All
centrally acting, appetite-inhibiting medi-
cations have now been withdrawn from
use in the UK because of mood-altering or
cardiac adverse events. However, anorectic
gut hormones, which are released post-
prandially and known to exert effects on
appetite control centers in the brain,
remain promising therapeutic targets.
Two such hormones are peptide YY (PYY)
and glucagon-like peptide 1 (GLP-1), both
of which are secreted by the gut in
response to a meal. The rationale is that
they may be used to chronically modulate
food intake via physiological pathways,
without inducing dangerous side effects.
Acute administration of PYY3–36 and
GLP-17–36 amide (the active forms of the
hormones) to humans is well established to
inhibit appetite and reduce food intake.3-6
Long-acting GLP-1 analogs, currently
licensed for the treatment of Type 2
diabetes, have been shown to be associ-
ated with significant weight loss when
administered to non-diabetic individuals.7
Likewise, long acting PYY analogs are
in development. Furthermore, following
Roux-en-Y gastric bypass surgery (the most
effective current treatment for obesity),
patients have elevated post-prandial
levels of both PYY and GLP-1, and the
combined actions of these peptides are
thought to contribute to the greater and
sustained weight loss observed following
the intervention.8,9 Thus, clarifying the
neuroendocrinology of gut hormones,
acting both independently and together,
is hugely important for the development of
effective obesity treatments.
PYY and GLP-1 Reduce Food
Intake and Neuronal Activity
in Brain Appetite Centers
In humans, functional MRI (fMRI) imag-
ing offers an opportunity to study the
effects of these hormones on the brain. In
a recently published study, we examined
the independent and combined effects
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of PYY3–36 and GLP-17–36 amide on
subsequent food intake and neuronal
activity in regions of the brain contri-
buting to appetitive processing and beha-
vior.10 Fifteen healthy, lean subjects were
scanned on five separate occasions at least
three days apart, during which they
received each of the following interven-
tions in random order: a saline infusion
following an overnight fast (the fasted,
control visit); a saline infusion following
a large breakfast (the fed visit); an infu-
sion of PYY3–36; an infusion of GLP-
17–36 amide; a combined infusion of
PYY3–36 + GLP-17–36 amide (all the gut
hormone infusions were performed after
an overnight fast). The subjects were then
served a free intake buffet lunch at the
end of each infusion, in order to assess
effects on food intake. As expected, after
subjects consumed breakfast, they ate
significantly less at lunch than if they
had continued fasting through the morn-
ing. Administering either of the gut
hormones PYY3–36 or GLP-17–36 amide
to our fasted subjects also reduced the
amount of food they consumed at lunch,
although to a smaller extent. Notably,
when PYY3–36 and GLP-17–36 amide were
co-administered to fasted subjects, food
consumption at lunch was comparable to
that observed in subjects who had eaten
breakfast. While our experimental pro-
cedure was not designed to draw conclu-
sions about dose-response relationships for
the effects of these hormones, the effects of
combined gut hormone infusion appeared
to be additive, with no loss of potency
when the hormones were administered in
combination. We postulate that admini-
stration of these anorectic gut hormones
in combination induces the satiety similar
or identical to that of a meal, but without
the associated caloric load. This holds
promise for the future development of
these hormones as anti-obesity agents.
During the course of each of the
infusions described above, using blood-
oxygen level-dependent (BOLD) fMRI,
we tested for differences in relative acti-
vation in several pre-selected brain regions
of interest (ROIs) when subjects viewed
images of food compared with images of
non-food items. This difference in relative
brain activation when viewing images
of food compared with non-food was
attenuated in the insula after a full break-
fast, with similar trends in the caudate
and putamen (dorsal striatum), nucleus
accumbens (ventral striatum) and orbito-
frontal cortex. Our findings are largely
consistent with recent studies demon-
strating that fasting selectively increases
BOLD fMRI activation to pictures of
high-calorie food compared with pictures
of low calorie food in similar ROIs and
that this activation is attenuated in the fed
state.11,12 Notably, we did not observe a
fed-fasted difference within the amygdala,
in contrast to the earlier study by La Bar et
al.13 In our recent study, PYY3–36 or GLP-
17–36 amide infusion resulted in a similar
attenuation of activation in all of the above
pre-selected ROIs, and infusion of both
hormones to fasted individuals resulted
in an overall pattern of brain activation
comparable with that observed in the fed
state. The ROIs were selected based on
their known involvement in reward pro-
cessing and response to food. As with the
reduction in food intake, the reduction in
BOLD signal after the combined admin-
istration of PYY3–36 and GLP-17–36 amide
was similar to the sum of the effects of
each individual hormone, again suggestive
of their action in concert. In summary, our
results suggest that PYY and GLP-1 act
in the brain to make food intake cues
less salient. Combined administration of
these anorectic gut hormones to a fasted
individual is associated with brain activa-
tion and behavioral changes similar to
those after eating a full meal.
This fascinating insight into the neuro-
endocrinology of appetite highlights
numerous new questions for future
studies. In our study, the lack of any
obvious differential activation pattern
between PYY3–36 and GLP-17–36 amide
suggests that these hormones may be
acting on the brain via a common
pathway. One explanation is that circulat-
ing gut hormones activate key homeostatic
regions in the brainstem and hypo-
thalamus, either directly through action
in brain regions without a limiting blood
brain barrier, or indirectly via vagal
afferents. The functional anatomical loca-
lizations of brain activations after hormone
administration suggest that ascending
connections from vagal nuclei modulate
the dopaminergic reward system: it was in
the insular cortex (which is situated at an
interface of homeostatic and cognitive
systems with activity related to establishing
salience of external stimuli for appropriate
behavioral reactions14) that we observed
brain activity to be most significantly
modulated by both feeding and gut
hormone infusion. Another region where
we observed changes was in the nucleus
accumbens (forming the major part of the
ventral striatum); this area is thought to
play an important role in the mediation
of hedonic drive and action (e.g., food-
seeking behaviors).15
Recent evidence has identified a role
for the orbitofrontal cortex in linking food
memory with food reward. Connectivities
of the orbitofrontal cortex with the
hippocampus, amygdala and insula16 may
facilitate a central role in coordinating
appetitive behavior. Indeed, a previous
fMRI study reported a relationship
between orbitofrontal cortex BOLD signal
and food intake when PYY3–36 was
infused, suggesting that the orbitofrontal
cortex may mediate a PYY3–36 induced
switch in the regulation of food intake
from homeostatic to hedonic control.17
Comparison of the Effects of PYY
and GLP-1 on Neuronal Activity
Related to Appetite with Those of
Other Appetite-Modulating
Hormones
It is of interest to interpret our results
in the context of similar human fMRI
studies investigating neuronal effects of
other appetite-modulating hormones.
Consistent trends can be found in reports
of modulation of the fMRI BOLD signal
when viewing food-related images in the
presence or absence of these hormones,
with the directionality of neuronal effects
seemingly dependent on whether the
hormone under scrutiny is anorectic or
orexigenic.
Leptin, a hormone secreted by adipo-
cytes, is thought to form part of the
feedback loop for maintaining long-term
energy homeostasis; when fat stores are
replete, increased levels of leptin signal to
the brain to reduce subsequent food intake
in order to maintain weight neutrality.
However, while this is an oversimplifica-
tion, given the well known phenomenon
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of leptin resistance in obesity, in global
terms, we may consider leptin to be an
anorectic hormone. In an fMRI study that
used a protocol similar to ours, when leptin
was replaced subcutaneously in individuals
with congenital leptin deficiency, BOLD
activation was reduced in the caudate,
putamen, globus pallidus and nucleus
accumbens.18 In another fMRI study test-
ing for brain activation contrasts between
viewing high- and low-calorie food images
(i.e., slight methodological differences to
ours, as we used the signal contrast between
all food and non-food images), subcuta-
neous leptin replacement in congenitally
leptin deficient individuals resulted in
reduced BOLD activation in the insula,
temporal and parietal cortex.19 Therefore,
our results for PYY3–36 and GLP-17–36 amide
administration, showing attenuation of
signal in the insula, caudate, putamen and
nucleus accumbens, are consistent with
these previous studies of leptin.
It is also interesting to consider our
results in relation to the effects of the
hormone insulin on cue-induced brain
activation. Although exogenous insulin
therapy often leads to weight gain when
administered to patients with diabetes
(which may be consequential to its overall
peripheral anabolic effects and also due to
the stimulation of appetite secondary to a
fall in blood glucose), endogenous insulin
release is postprandial and central anorec-
tic effects limit further food intake. In a
study where insulin was administered
intranasally while maintaining euglycae-
mia, fMRI BOLD activation (in response
to food vs. non-food images) was reduced
in the fusiform gyri, right hippocampus,
right temporal superior cortex and right
frontal middle cortex.20 The attenuation
of BOLD signal in higher cortical centers
by insulin is consistent with our data.
We speculate that subtle differences in
brain responses between insulin and our
anorectic gut hormones PYY3–36 and
GLP-17–36 amide may reflect the different
roles of these hormones in energy home-
ostasis: anorectic gut hormones are
thought to mediate short-term signaling,
whereas insulin may be implicated both in
short and longer term signaling of energy
homeostasis.
Ghrelin is a potent orexigenic gut
hormone. In a BOLD fMRI study similar
to ours, relative brain activation with food
pictures was increased in the amygdala,
orbitofrontal cortex, insula, visual areas
and striatum, along with increased hunger
ratings in normal-weight subjects after
intravenous ghrelin infusion.21 To investi-
gate the effects of hypoglycemia (another
orexigenic stimulus), a recent study
reported increased BOLD activation in
the insula and striatum, along with
increased hunger after mild hypoglycemia
was induced.22 Thus we believe that our
work, along with other fMRI studies,
suggests that while anorectic hormones
attenuate activity in brain regions support-
ing salience and reward, orexigenic stimuli
enhance activation in these same areas.
Comparison of the Effects of PYY
and GLP-1 on Brain Activity with
Those Observed after Gastric
Bypass Surgery
In our original article, we reported the
plasma levels of the active forms of the
hormones, PYY3–36 and GLP-17–36 amide.10
We also measured total hormone levels
(using radioimmunoassays that addition-
ally pick up other forms of each hormone
which have lesser activity at the relevant
receptors) (unpublished data). Total hor-
mone concentrations are more commonly
reported in the literature; review of our
total hormone levels thus allows for
meaningful comparison with existing
relevant data. Our results revealed that
during the combined infusion of PYY3–36
and GLP-17–36 amide, the mean total PYY
concentration achieved was 70 pM and
the mean total GLP-1 concentration was
43 pM. Interestingly, the mean circulating
levels of total PYY and total GLP-1
following breakfast were 33 pM and
22 pM, respectively. Therefore, although
our infused circulating total PYY and
total GLP-1 levels were slightly higher
than those observed physiologically after
breakfast, they were of a similar order of
magnitude. Consistent with this, there
was a comparable reduction in ad libitum
energy intake at lunch following combined
infusion of PYY3–36 and GLP-17–36 amide
and following infusion of saline after a
large breakfast (fed visit).
Roux-en-Y gastric bypass is the most
effective current treatment for obesity,
leading to sustained weight loss of
approximately 30%.23 In a study by Le
Roux et al.,9 a mean 90 min post-prandial
total PYY level of 40 pM was observed
following Roux-en-Y gastric bypass. In the
same study, a mean 30 min post-prandial
total GLP-1 level of 47 pM was observed.
These levels are comparable to plasma
levels of total PYY and total GLP-1 that
were observed in our study. Therefore,
although circulating levels achieved in
our study may be regarded as somewhat
supraphysiological within the normal
population, they are of direct functional
relevance for understanding the effects of
PYY and GLP-1 in patients who have
undergone gastric bypass surgery. PYY and
GLP-1 appear to be the most important
gut hormones implicated in mediating
reduced appetite and promoting weight
loss following gastric bypass,24 although
there are likely to be changes in other
gut hormones that are not routinely
measured.
It is also of interest to compare our
imaging results in healthy, lean indivi-
duals to those found in an fMRI study
of obese individuals pre- and post-gastric
bypass surgery.25 Post-surgery (compared
with pre-surgery), there was attenuation
of high calorie food cue associated fMRI
BOLD signal in the ventral tegmental
area, ventral striatum, putamen, lentiform
nucleus, posterior cingulate and dorsome-
dial prefrontal cortex. Hunger also was
reduced after surgery.25 These results are
striking, given that we also found similar
attenuation of BOLD signal in reward
areas when we administered PYY3–36 and
GLP-17–36 amide. Although circulating
gut hormone levels were not measured
in the gastric bypass study, the authors
postulated post-surgical reductions in
ghrelin levels as an explanation for their
imaging observations. We speculate that
elevated levels of PYY and GLP-1 post-
bypass would explain their findings.
Thus, while functional MRI is at present
used only as a research tool in endo-
crinology, these studies imply translation
for the pre-operative work-up of obese
patients; it may help highlight those
patients who are more susceptible to the
anorectic effects of gut hormones and
whomay therefore benefit most from
surgery.
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Limitations of fMRI
Direct information on hypothalamic res-
ponses is not yet available. Unfortunately,
imaging the hypothalamus is inherently
difficult with a BOLD-based fMRI pro-
tocol because of its small size and proxi-
mity to the intracranial sinuses, which
cause local signal loss in the MRI image.
Thus, the ascending pathways mediating
actions of these circulating appetite sup-
pressants remain incompletely understood.
Although our ROIs were chosen based
on the results of existing data in the field
and also our hypotheses as to their role
in food reward, it should be noted that
an ROI-based analysis, although statist-
ically providing more sound results, pos-
sesses the inherent problem of potentially
missing other regions of the brain which
are modulated by gut hormones. Despite
the above limitations, our data confirm
an emerging view of gut hormones as
not simply modulating homeostatic
mechanisms governing appetitive behavior
but also the cognitive reward processing
of food.
Conclusion
There is a useful consensus emerging from
studies of functional brain imaging of
appetite control: anorectic hormones sup-
press brain activation in response to food
cues, whereas orexigenic signals activate
the same regions. Furthermore, we have
shown that by administering PYY3–36 and
GLP-17–36 amide to fasted individuals, it is
possible to ‘trick’ the brain into feeling
‘satiated’ in ways that appear indistin-
guishable from the effects of a meal. There
is additional exciting data to suggest that
following gastric bypass, where it is known
that appetite is reduced and that levels of
PYY and GLP-1 are elevated, patterns
of brain activation are similar to those
seen after administration of PYY3–36 and
GLP-17–36 amide in healthy volunteers.
We have speculated on the significance
of some of the brain areas engaged in
appetitive processing and suggest that a
continued and deeper understanding of
the neurobiology of appetite will pave the
way to the development of gut hormones
as effective anti-obesity therapies. Given
the consistency of the imaging data so far,
it seems plausible that the administration
of combined anorectic gut hormones may
provide an effective future medical alter-
native to a surgical gastric bypass pro-
cedure to treat obesity.
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